(c) Pixabay

Researchers at the Johannes Kepler University in Linz, Austria have developed a drug that enables the rapid treatment of heart attack patients on site. 5`-Methoxyleoligin can be administered intravenously by emergency doctors. Myocardial infarction is the most frequent cause of death in Austria. A rapid medical intervention can save the lives of those affected. Until now, this procedure could only be performed in hospital. Professor David Bernhard, head of the Centre for Medical Research at the Johannes Kepler University Linz, has now developed 5`-Methoxyleoligin – an active substance that replaces this intervention and can be used by emergency doctors on site in the form of a syringe.

Read all the articles in our archive by becoming a member of Innovation Origins. Sign up here as a supporter of independent journalism!

Become a member!

On Innovation Origins you can read the latest news about the world of innovation every day. We want to keep it that way, but we can't do it alone! Are you enjoying our articles and would you like to support independent journalism? Become a member and read our stories guaranteed ad-free.

About the author

Author profile picture Hildegard Suntinger is a writer. She lives in Vienna as a freelance journalist and writes about all aspects of fashion production. She is interested in new trends in design, technology, and business. She is particularly excited about discovering interdisciplinary tendencies and the blurring of boundaries between different disciplines. The key element is technology, which changes all areas of life and work.